Key Segments:
By Indication
- Large B-Cell Lymphoma
-
Multiple Myeloma
-
Acute Lymphoblastic Leukemia (ALL)
-
Melanoma (lesions)
-
Others
By Route of Administration
-
Intravenous
-
Others
By Vector Type
-
Lentivirus
-
RetroVirus & gamma RetroVirus
-
AAV
-
Modified Herpes Simplex Virus
-
Adenovirus
-
Others
By End User
-
Cancer Research Institutes
-
Diagnostic Centers
-
Others (Hospitals and biotechnology Companies)
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Cancer Gene Therapy Market in 2024.
The “Intravenous” segment dominated the Cancer Gene Therapy Market.
Advancements in gene editing and vector technologies are accelerating the market growth.
The Cancer Gene Therapy Market was USD 4.07 billion in 2024 and is expected to reach USD 17.35 billion by 2032.
The Cancer Gene Therapy Market is expected to grow at a CAGR of 19.96% from 2025 to 2032.